Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA’s approved drug Lantus in reducing patients’ blood sugar levels in three late-stage trials.
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy